Innate Pharma Files 2025 Annual Report and Universal Registration Document

Innate Pharma S.A. (Nasdaq: IPHA) announced the filing of its 2025 Universal Registration Document with the French Autorité des Marchés Financiers (AMF) and its 2025 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) on April 1, 2026. These comprehensive reports include the company's annual financial statements, management reports, and corporate governance details for the fiscal year ending December 31, 2025. The filings provide updates on Innate's clinical-stage portfolio, which includes IPH4502 (a Nectin-4 ADC), lacutamab (anti-KIR3DL2), and monalizumab (anti-NKG2A), the latter being developed in collaboration with AstraZeneca. The company continues to focus on developing next-generation antibody therapeutics for cancer patients with high unmet medical needs. No new clinical data or changes to trial timelines were disclosed in this administrative filing announcement. The documents are now available for public review on the company's website and through respective regulatory portals.